Under construction – not a live service
Sign in
Taking peoplePhase 3

Compares mezigdomide with pomalidomide in relapsed or refractory multiple myeloma

Tests mezigdomide, bortezomib and dexamethasone against pomalidomide combination in adults with myeloma.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Key facts

Where
Abilene, Albuquerque, Allentown, Ann Arbor, Athens, Aurora, Baltimore, Baton Rouge, Boston, Buffalo, Cincinnati, Cleveland, Coral Springs, Detroit, Durham, East Brunswick, Farmington, Fort Myers, Fredericksburg, Garden City, Germantown, Hattiesburg, Houston, Jackson, Lake Success, Los Alamitos, Madison, Marietta, Mayfield Heights, Minneapolis, New Haven, New Hyde Park, New Orleans, New York, Norfolk, Orange City, Ridgewood, Roanoke, Rochester, Salt Lake City, San Antonio, San Diego, Seattle, Shirley, Shreveport, Spokane, The Bronx, Vancouver, West Hollywood, West Palm Beach, Westwood, Williamsville, and York, United StatesSee the 56 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which of these best describes your myeloma treatment so far?
  • Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
  • Has a doctor told you that your myeloma can be measured in your blood or urine tests?

Source: NCT05519085, who can take part

Where in United States

  • AbileneAbilene, United StatesNo longer taking part
  • AlbuquerqueAlbuquerque, United StatesNo longer taking part
  • AllentownAllentown, United StatesNo longer taking part
  • Ann ArborAnn Arbor, United StatesNo longer taking part
  • AthensAthens, United StatesNo longer taking part
  • AuroraAurora, United StatesNot yet recruiting
  • BaltimoreBaltimore, United StatesNo longer taking part
  • Baton RougeBaton Rouge, United StatesNo longer taking part
  • BostonBoston, United StatesNo longer taking part
  • BuffaloBuffalo, United StatesNo longer taking part
  • CincinnatiCincinnati, United StatesNo longer taking part
  • ClevelandCleveland, United StatesNo longer taking part
  • ClevelandCleveland, United StatesNo longer taking part
  • Coral SpringsCoral Springs, United StatesNo longer taking part
  • DetroitDetroit, United StatesNo longer taking part
  • DurhamDurham, United StatesNo longer taking part
  • East BrunswickEast Brunswick, United StatesNo longer taking part
  • FarmingtonFarmington, United StatesNo longer taking part
  • Fort MyersFort Myers, United StatesNo longer taking part
  • FredericksburgFredericksburg, United StatesNo longer taking part
  • Garden CityGarden City, United StatesNo longer taking part
  • GermantownGermantown, United StatesNo longer taking part
  • HattiesburgHattiesburg, United StatesNo longer taking part
  • HoustonHouston, United StatesNo longer taking part
  • JacksonJackson, United StatesNo longer taking part
  • Lake SuccessLake Success, United StatesNo longer taking part
  • Los AlamitosLos Alamitos, United StatesNo longer taking part
  • MadisonMadison, United StatesNo longer taking part
  • MariettaMarietta, United StatesNo longer taking part
  • Mayfield HeightsMayfield Heights, United StatesNo longer taking part
  • MinneapolisMinneapolis, United StatesNo longer taking part
  • New HavenNew Haven, United StatesNo longer taking part
  • New Hyde ParkNew Hyde Park, United StatesNo longer taking part
  • New OrleansNew Orleans, United StatesNo longer taking part
  • New YorkNew York, United StatesNo longer taking part
  • NorfolkNorfolk, United StatesNo longer taking part
  • Orange CityOrange City, United StatesNo longer taking part
  • RidgewoodRidgewood, United StatesNot yet recruiting
  • RoanokeRoanoke, United StatesNo longer taking part
  • RochesterRochester, United StatesNo longer taking part
  • Salt Lake CitySalt Lake City, United StatesNo longer taking part
  • San AntonioSan Antonio, United StatesNo longer taking part
  • San AntonioSan Antonio, United StatesNo longer taking part
  • San DiegoSan Diego, United StatesNo longer taking part
  • SeattleSeattle, United StatesNo longer taking part
  • SeattleSeattle, United StatesNo longer taking part
  • ShirleyShirley, United StatesNo longer taking part
  • ShreveportShreveport, United StatesNot yet recruiting
  • SpokaneSpokane, United StatesNo longer taking part
  • The BronxThe Bronx, United StatesNo longer taking part
  • VancouverVancouver, United StatesNo longer taking part
  • West HollywoodWest Hollywood, United StatesNo longer taking part
  • West Palm BeachWest Palm Beach, United StatesNo longer taking part
  • WestwoodWestwood, United StatesNo longer taking part
  • WilliamsvilleWilliamsville, United StatesNo longer taking part
  • YorkYork, United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Celgene
Trial code
NCT05519085
Record updated
30 October 2026
Original description
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.Read full original descriptionShow less

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Inclusion: Participant has documented diagnosis of MM and measurable disease, defined as any of the following:; M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or; M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP); For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio; Participants received 1 to 3 prior lines of antimyeloma therapy; Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.

Exclusion: Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:; Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded; Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded; For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity; Participant has had prior treatment with mezigdomide or pomalidomide; Other protocol-defined Inclusion/Exclusion criteria apply.

ClinicalTrials.gov NCT05519085